➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Moodys
Baxter
Medtronic
McKinsey
Dow
McKesson

Last Updated: October 16, 2021

DrugPatentWatch Database Preview

Claims for Patent: 4,704,383

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

Summary for Patent: 4,704,383
Title: Non-antibacterial tetracycline compositions possessing anti-collagenolytic properties and methods of preparing and using same
Abstract:Tetracyclines having substantially no effective antibiotic or antibacterial activity and possessing anti-collagen-destructive enzyme activity or anti-collagenase activity and compositions containing the same have been found useful as anti-collagenolytic agents. Such tetracyclines and compositions containing the same are useful in the treatment of periodontal diseases, corneal ulcers, bone deficiency disorders, rheumatoid arthritis diseases characterized by excessive collagen destruction. A special aspect of this invention involves the incorporation of such tetracyclines in animal feed compositions for improved animal nutrition, such as may be evidenced by increased weight gain.
Inventor(s): McNamara; Thomas F. (Port Jefferson, NY), Ramamurthy; Nungavaram S. (Smithtown, NY), Golub; Lorne M. (Smithtown, NY)
Assignee: The Research Foundation of State University of New York (Albany, NY)
Application Number:06/699,048
Patent Claims:1. A method for treating humans or animals suffering from a condition or disease characterized by excessive collagen destruction due to collagen-destructive enzymes which comprises administering to said human or animal an effective anti-collagenase amount of tetracycline having substantially no effective antibiotic or antibacterial activity.

2. A method in accordance with claim 1 wherein said tetracycline is dedimethylaminotetracycline.

3. A method in accordance with claim 1 wherein said excessive collagen destruction is evidenced by ulceration of the cornea.

4. A method in accordance with claim 1 wherein said excessive collagen destruction is evidenced by periodontal disease.

5. A method in accordance with claim 1 wherein said excessive collagen destruction is evidenced by rheumatoid arthritis.

Details for Patent 4,704,383

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Smith And Nephew SANTYL collagenase OINTMENT;TOPICAL 101995 1965-06-04 ⤷  Free Forever Trial The Research Foundation of State University of New York (Albany, NY) 2004-11-03 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

International Patent Family for US Patent 4,704,383

Country Patent Number Estimated Expiration
South Africa 86838 ⤷  Free Forever Trial
United States of America 4666897 ⤷  Free Forever Trial
United States of America 4925833 ⤷  Free Forever Trial
United States of America 4935411 ⤷  Free Forever Trial
United States of America 4935412 ⤷  Free Forever Trial
United States of America RE34656 ⤷  Free Forever Trial
>Country >Patent Number >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Merck
Express Scripts
McKesson
AstraZeneca
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.